-

Robbins LLP Encourages EOSE Stockholders to Contact the Firm for Information About the Class Action Against Eos Energy Enterprises, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Eos Energy Enterprises, Inc. (NASDAQ: EOSE) securities between November 5, 2025 and February 26, 2026. Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems intended for utility-scale commercial and industrial applications.

Robbins LLP is Investigating Allegations that Eos Energy Enterprises, Inc. (EOSE) Misled Investors Regarding its Business Prospects

Share

For more information, submit a formemail attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is the class period? November 5, 2025 – February 26, 2026

What are the allegations? Robbins LLP is Investigating Allegations that Eos Energy Enterprises, Inc. (EOSE) Misled Investors Regarding its Business Prospects

According to the complaint, during the class period, defendants failed to disclose that: (1) the Company was unable to achieve the ramp in production and capacity utilization required to achieve its previously set guidance; (2) the Company’s battery line downtime was running well above industry norms, the design intent of the line, and internal forecasts; (3) the Company was experiencing delays in the ability for its automated bipolar production to hit quality targets; and (4) the Company’s inadequate systems and processes prevented it from ensuring reasonably accurate guidance and that its public disclosures were timely, accurate, and complete.

Plaintiff alleges that on February 26, 2026, Eos Energy announced disappointing fourth quarter and full year 2025 results, reporting, among other things, full year 2025 revenue of $114.2 million, falling far short of the Company’s previously issued guidance of $150 million to $160 million for fiscal year 2025 revenue. The Company further reported a “gross loss of $143.8 million,” a “net loss attributable to shareholders of $969.6 million,” and an “adjusted EBITDA loss of $219.1 million.” Further, on the Company's earnings call, the CEO disclosed that certain “issues prevented us from delivering our commitments,” including that “battery line downtime ran well above industry norms, the design intent of the line and our internal forecast,” and “the ability for the automated bipolar production to hit quality targets took longer than expected. That drove rework and lost revenue.” On this news, Eos Energy’s stock price fell $4.39, or 39.4%, to close at $6.74 per share on February 26, 2026.

What can shareholders do now? You may be eligible to participate in the class action against Eos Energy Enterprises, Inc. Shareholders who wish to serve as lead plaintiff for the class must file their papers with the court by May 5, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Eos Energy Enterprises, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:EOSE

Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Robbins LLP Urges Investors Who Lost Money Investing in Upstart Holdings, Inc. to Contact the Firm for Information About Leading the Class Action Against UPST

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Upstart Holdings, Inc. (NASDAQ: UPST) securities between May 14, 2025 and November 4, 2025. Upstart, together with its subsidiaries, operates a cloud-based artificial intelligence (“AI”) lending platform in the U.S.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.What is the class period?...

Robbins LLP Urges Investors Who Lost Money Investing in Stellantis N.V. to Contact the Firm for Information About Leading the Class Action Against STLA

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Stellantis N.V. (NYSE: STLA) securities between February 26, 2025 and February 5, 2026. Stellantis is a global automobile designer, engineer, manufacturer, and distributor.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.What is the class period? February 26, 2025 – February 5, 2026What a...

Robbins LLP Urges Investors Who Lost Money Investing in Medpace Holdings Inc. to Contact the Firm for Information About Leading the Class Action Against MEDP

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Medpace Holdings Inc. (NASDAQ: MEDP) securities between April 22, 2025 and February 9, 2026. Medpace is a clinical contract research organization (CRO) focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.For more information, submit a form, email...
Back to Newsroom